MEDICAL CHEMICAL DEFENSE (EMD)

Abstract

This project provides for the development of medical materiel and other medical equipment items necessary to provide an effective capability for medical defense against chemical warfare agent threats facing U.S. forces in the field. This project supports efforts in the Engineering and Manufacturing Development (EMD) phase of the acquisition strategy for prophylactic, pre-treatment, and therapeutic drugs and diagnostic medical devices for the protection, treatment, detection, and medical management of chemical warfare agent exposures. Project provides for the research and development of safety studies, manufacturing scale-up, process validation, drug interaction, performance test, and submission of the Food and Drug Administration (FDA) drug licensure application(s). This program currently includes: (1) Alternative Autoinjector (AUTOINJ), which consists of investigating an FDA approved alternative source(s), beyond the single current DoD source, for autoinjectors that deliver DoD nerve agent antidote and treatment capabilities to the warfighter; mitigates capability fielding and operational readiness risks. This resulted from the manufacturing and quality issues for the Advanced Anticonvulsant System (AAS) program, Midazolam in an autoinjector. (2) Bioscavenger (BSCAV), a new capability, to be used as a prophylaxis against nerve agents; (3) Improved Nerve Agent Treatment System (INATS) an enhanced nerve agent treatment regimen consisting of an improved oxime to replace the current fielded oxime 2-pralidoxime chloride (2-PAM), a centrally acting therapeutic to increase survival, and studies to generate data to support use of pyridostigmine bromide (PB), as a pretreatment for nerve agents in addition to soman.

Open PDF

Document Details

Document Type
Project
Publication Date
Oct 01, 2017
Source ID
MC5_0604384BP_5_0400_PB_2017

Tags

Fields of Study

  • Medicine

Readers

  • Critical Infrastructure Protection in CBRN and WMD Threats.
  • Neurotoxicology

Related Documents